ABIO Share Price

Open 1.15 Change Price %
High 1.15 1 Day -0.10 -8.70
Low 1.05 1 Week -0.15 -12.50
Close 1.05 1 Month -1.37 -56.61
Volume 138198 1 Year -1.92 -64.65
52 Week High 3.11
52 Week Low 1.05
ABIO Important Levels
Resistance 2 1.14
Resistance 1 1.10
Pivot 1.08
Support 1 1.00
Support 2 0.96
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.13 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
VRTA 4.50 38.46%
ATEA 2.50 32.98%
ATEA 2.50 32.98%
KIRK 10.98 31.03%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TWER 0.10 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

ARCA biopharma, Inc. (NASDAQ: ABIO)

ABIO Technical Analysis 5
As on 22nd Aug 2017 ABIO Share Price closed @ 1.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.43 & Strong Sell for SHORT-TERM with Stoploss of 2.13 we also expect STOCK to react on Following IMPORTANT LEVELS.
ABIO Target for August
1st Target up-side 2.43
2nd Target up-side 2.83
3rd Target up-side 3.24
1st Target down-side 1.27
2nd Target down-side 0.87
3rd Target down-side 0.46
ABIO Other Details
Segment EQ
Market Capital 4122726.75
Sector Healthcare
Industry Biotechnology
Offical website http://www.arcabiopharma.com
ABIO Address
ABIO
11080 CirclePoint Road
Suite 140
Westminster, CO 80020
United States
Phone: 720-940-2200
ABIO Latest News
Interactive Technical Analysis Chart ARCA biopharma, Inc. ( ABIO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ARCA biopharma, Inc.
ABIO Business Profile
ARCA biopharma, Inc. (ARCA), incorporated in 1992, is a bio-pharmaceutical company. The Company’s principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.The Company has collaborated with LabCorp to develop the Gencaro Test, a companion test for the genetic markers that may predict clinical response to Gencaro. ARCA’s product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro (bucindolol hydrochloride) is a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of AF. Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2 receptors in the cardiac nervous system. The Company Address is Suite 200, 8001 Arista Place, BROOMFIELD CO 80021.